Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation reports developments tied to its specialty ingredient manufacturing business for health, nutrition, agriculture, healthcare, and other industrial markets. The company operates through Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, with recurring updates on segment sales, earnings, cash flow, debt, share repurchases, and conference participation.
Company news also includes product and market developments such as customized food and beverage ingredient systems, key nutrients for food, supplement, and pharmaceutical applications, animal nutrition products, choline chloride, specialty-packaged chemicals, and chelated minerals for micronutrient agriculture. Updates have included the Metalosate® T.E.A.M.™ plant tissue analysis platform and trade actions affecting choline chloride supply chains.
Balchem Corporation (NASDAQ: BCPC) announced a dividend of $0.71 per share on December 5, 2022, marking a 10.9% increase from the previous year. This dividend will be paid on January 20, 2023, to shareholders on record as of December 27, 2022. The announcement signifies the fourteenth consecutive annual dividend increase, highlighting the company's robust financial performance and the Board's confidence in its long-term strategies.
Balchem Corporation (NASDAQ: BCPC) reported a net earnings increase to $25.2 million for Q3 2022, compared to $25.0 million in Q3 2021. Adjusted net earnings rose to $32.4 million, up 8% year-over-year, with adjusted EBITDA at $53.8 million, reflecting an 11.2% increase.
Net sales reached $244.3 million, a 23.4% increase driven by growth in all segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The effective tax rate declined to 18.8%. Cash flows from operations were $41.6 million, with free cash flow at $26.8 million.
Balchem Corporation (NASDAQ: BCPC) will host a conference call on November 4, 2022, at 11:00 AM ET to discuss its third quarter results. The financial results will be released before market opening on the same day. Interested parties can join the call by dialing 1-877-407-8289 or 1-201-689-8341 locally. A replay will be available until November 18, 2022, using conference ID #13733850. Balchem focuses on developing specialty ingredients across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ:BCPC) has announced its acquisition of Cardinal Associates Inc., known as Bergstrom Nutrition, a leading producer of methylsulfonylmethane (MSM) based in Vancouver, Washington. This strategic purchase enhances Balchem's product portfolio, particularly in joint health, sports nutrition, and beauty sectors. Bergstrom's OptiMSM® is recognized for its quality, holding a U.S. GRAS designation. The integration aims to accelerate growth and expand marketplace opportunities in Balchem's Human Nutrition and Health segment, aligning with its focus on longevity and performance.
Balchem Corporation (NASDAQ: BCPC) reported a strong second quarter for 2022, with net earnings of $29.8 million, up 31% from $22.7 million in Q2 2021. Adjusted net earnings rose to $34.4 million, reflecting a 13.3% increase year-over-year. Record net sales reached $236.7 million, marking a 17.0% growth, driven by Human, Animal, and Specialty Nutrition segments. The company completed the acquisition of Kappa Bioscience, enhancing its portfolio in the nutrition sector. Operational cash flow was robust at $48.2 million.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on July 29, 2022, at 11:00 AM ET to discuss its second quarter results, which will be published before market opening on the same day. CEO Ted Harris and CFO Martin Bengtsson will lead the call. Participants can access the conference by calling toll-free 1-877-407-8289. A replay will be available from two hours post-conclusion until August 12, 2022, using conference ID #13731403. For more information, visit www.balchem.com.
Balchem Corporation (NASDAQ:BCPC) has successfully completed its acquisition of Kappa Bioscience AS, a leading manufacturer of specialty vitamin K2, enhancing its portfolio in the human nutrition sector. This acquisition, initially announced on June 14, 2022, aims to capitalize on the growing demand for vitamin K2, which is vital for bone health, heart health, and immunity. Kappa's K2VITAL® is recognized for its purity and stability, backed by strong intellectual property and clinical research.
Balchem Corporation (NASDAQ:BCPC) announced the acquisition of Kappa Bioscience AS for an enterprise value of NOK 3.175B (approximately USD 338M). Kappa specializes in vitamin K2, essential for bone and heart health. This acquisition enhances Balchem's portfolio in science-based nutrients, expected to be accretive to earnings per share in 2022. Kappa's projected 2022 revenue is approximately NOK 500M (USD 53M). The deal will strengthen Balchem's market presence in Europe and the U.S., while Kappa will benefit from Balchem's established distribution network.
Balchem Corporation (NASDAQ: BCPC) reported a strong first quarter of 2022, with net earnings of $28.9 million and record net sales of $228.9 million, up 23.3% from the previous year. Adjusted net earnings rose to $33.4 million, reflecting a 17.3% increase, with earnings per share reaching $1.03. All three business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—experienced double-digit sales growth. Despite rising operational costs, the company maintained solid profit margins and plans to further enhance its sustainability efforts.
Summary not available.